Navigation Links
Complement in Medical Technology

Potentia Pharmaceuticals' POT-4 Drug Candidate for Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial - Prepares for Phase II

... affected by it." About POT-4 POT-4 is a complement factor C3 inhibitor, which shuts down the complement activation cascade that could otherwise lead to ... "dry" form of the disease. About the complement System and POT-4 ...

Optherion Announces Issuance of Canadian Patents Covering Age-Related Macular Degeneration Diagnostics and Treatments

... other chronic diseases involving the alternative complement system, announced today that the Canadian Patent ... genetic modifications in several genes including complement factor H (CFH), complement factor B ...

Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH

... titled, "Safety and Efficacy of the Terminal complement Inhibitor Eculizumab in Japanese Patients with ... et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of ... (2) Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal ...

First Clinical Experience With Soliris(R) in Treating Patients With Two Rare Complement-Mediated Diseases Presented at ASH Annual Meeting

... Soliris(R) (eculizumab), a terminal complement inhibitor developed by Alexion Pharmaceuticals, ... patients with aHUS are missing or have defective complement inhibitors that help to regulate the body's ... attack on their red blood cells leading to severe complement activation and hemolysis (destruction of those ...

In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop

... were presented at the XXII International complement Workshop in Basel, Switzerland. The data ... expertise and expanding knowledge base within the complement research community," said Michael Holers, M.D., ... of the effects of modulation of the complement system on animal models of human disease," said ...

Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4

... First complement inhibitor to be tested in AMD patients ... safety results in its Phase I study. POT-4 is a complement inhibitor, which shuts down the complement activation cascade that could otherwise lead to ...

Data from In Vivo Disease Models on Taligen Therapeutics' Pipeline Candidates to be Presented at the XXII International Complement Workshop

... be presented next week at the XXII International complement Workshop in Basel, Switzerland. The data, which ... and the company's academic collaborators in the complement research community. Five studies testing the ... Taligen's approach that targeting the alternative complement pathway can impact ...

InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)

... will be presented at the XXII International complement Workshop in Basel, Switzerland, September ... of C3, the hub of the complement cascade. complement protein C3 is the master regulator of complement ... proteins for the controlled depletion of complement protein C3. The therapeutic potential for ...

Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters

... that Modulate Alternative Pathway of complement System CAMBRIDGE, Mass., July 23 /PRNewswire/ ... that are closely aligned with an international complement biology research network organized by Michael ... to modulate the alternative pathway of the complement system," said Dr. Emlen. "We are currently ...

Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus

... events over time. -- An increase in C3 and C4 complement among patients with low complement at baseline. About the Phase 2 Study of ... normalization of autoantibody, immunoglobulin and complement levels over three years of treatment ...

Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant

... Company will also require, at a minimum, one additional Phase III study to complement study IT-A-008 in order to pursue FDA approval and licensure. Update ... ability to complete, at a minimum, an additional Phase III study to complement study IT-A-008 in order to pursue FDA approval and licensure, the ...

deCODE and Radboud University Discover Common Variants in the Human Genome Conferring Risk of Bladder Cancer

... Detection may be used to complement and target screening for the disease; findings will be integrated into ... the detection of these and other risk variants will soon be employed to complement the assessment of standard risk factors for bladder cancer. As with all of ...

deCODE and SGENE Consortium Discover Deletions in the Human Genome Linked to Risk of Schizophrenia

... Findings may provide the foundation for a test to complement standard clinical diagnosis, potentially enabling earlier intervention and ... them a valuable basis upon which to develop molecular diagnostic tests to complement standard clinical diagnosis. The study, 'Large recurrent microdeletions ...

NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients

... mg tid (three times daily). The data from the 111 and 112 studies will complement the results of a 2-week ABPM study with naproxcinod compared to naproxen ... at the American Heart Association (AHA) in November 2007. They will also complement the Office Blood Pressure Measurements (OBPMs) being collected in each of ...

Soliris(R) Improved Fatigue Independent of Changes in Anemia in Patients with PNH by Controlling Hemolysis

... 2007; 100:4123-4128. (6)Hillmen P, Young NS, Schubert J et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J ... Brodsky RA, Young NS, Antonioli E et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal ...

Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan

... RA, Young, NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal ... 2008;111:1840-1847. (2) Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl ...

Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan

... Young, NS, Antonioli E., et al. Multicenter phase III study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal ... browser window.) (2) Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl ...

Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients

... online publication in Blood, titled "Multicenter phase III study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal ... 2005;106:3699-3709. (4) Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J ...

Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus

... at baseline normalized at Weeks 52-128. -- An increase in C3 and C4 complement among patients with low complement at baseline. -- Reversion of autoantibody levels from positive to ...

Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD

... ophthalmic diseases, and it also intends to market diagnostic systems that complement its therapeutic products. The company recently announced it has entered ... for opthalmic diseases, our ability to market diagnostic systems that complement our therapeutic products, as well as other non-historical statements about ...

FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS)

... to working with the agency throughout the review process," said Cynthia Schwalm, President of Eisai Inc. "This application is one part of a full complement of clinical development programs we have committed for Dacogen and is a vital part of our human health care mission of increasing patient benefits ...

Acura and King Receive FDA Complete Response Letter Regarding Acurox(R)

... including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products and technologies that complement the Company's focus in specialty-driven markets, particularly neuroscience and hospital. King's wholly-owned subsidiary, Alpharma, Inc., is also a ...

King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use

... including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products and technologies that complement the Company's focus in specialty-driven markets, particularly neuroscience and hospital. King's wholly-owned subsidiary, Alpharma, Inc., is also a ...

In Rare Disorder, a Familiar Protein Disrupts Gene Function

... The researchers used DNA microarrays, manufactured chips that measure how strongly different genes are expressed throughout a cell's full complement of DNA. The study team identified hundreds of genes that were dysregulated compared to controls, and also detected gene expression profiles that were ...

Kensey Nash Announces Presentations on its Cartilage Repair Device at the International Cartilage Repair Society Meeting

... The design also allows implants to be cut to length and easily hydrated with autologous blood products. The Company has also developed a full complement of specialized instruments to prepare the defect site for delivery of this proprietary bi-phasic implant. The Company is currently in discussion ...

TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009

... treatment, including agents that inhibit angiogenesis. TRACON addresses unmet needs in these areas with first-in-class product candidates that will complement existing therapies. TRC093 is a monoclonal antibody that binds to cleaved collagen to inhibit angiogenesis and tumor growth that began dosing in a ...

Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients

... which plans to file a Biologic License Application (BLA) for NT-201 in the USA in the near future. "The data to be presented at AAN complement the European data. We now have robust U.S. data for Xeomin (the brand name for NT-201 in Europe) for the symptomatic management of movement ...

Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimer's Disease

... a small-scale safety and tolerability trial of Dimebon added to donepezil, which found the combination to be well tolerated. CONCERT is designed to complement previous and ongoing studies by further evaluating the efficacy of Dimebon. The Phase 3 program also includes the confirmatory 6-month CONNECTION ...

Michael J. Fox Foundation Commits up to $6.5 Million in Funding for Critical Challenges in Parkinson's Disease

... funding and expertise can make the greatest difference in speeding scientific developments toward the clinic and patients." Critical Challenges complement the Foundation's annually recurring Pipeline Programs, which do not identify a specific research priority area to be pursued, but instead provide ...

Astrocytes Help Separate Man From Mouse

... participants in brain function and sensory processing." The brain's two signaling systems - one composed of neurons, and one of astrocytes - complement each other, Nedergaard said. Neurons send signals extremely quickly over long distances - the hand touches a hot stove, for instance, and the brain ...

FDA Submission of B-R-A-H-M-S MR-proANP Kryptor

... meeting, the results of the BACH-trial confirm the company's commitment to improving healthcare through highly effective biomarker tests and complement the success of the Procalcitonin Kryptor, the company's test for the diagnosis of severe bacterial infections, introduced in the U.S. in early 2008. ...

Kensey Nash Announces IDE Submission for Cartilage Repair Device

... The design also allows implants to be cut to length and easily hydrated with autologous blood products. The Company has also developed a full complement of specialized color-coded instruments to estimate implant size and prepare the defect site for the delivery of this proprietary bi-phasic implant. ...

Transgenomic and Power3 Medical Complete Agreement for Exclusive License of Neurodegenerative Biomarker Test

... disease fitting within Transgenomic's focus on disorders originating from mitochondrial damage. NuroPro will add significant depth to complement our array of genetic tests in neurology." Power3 Medical CEO Helen R. Park said, "This new licensing agreement provides Transgenomic with the ...

Breakthrough in Prenatal Screening for Down Syndrome

... and negatives drives better patient care, and that's exciting for the future." "Our preliminary results are extraordinarily encouraging, and complement nicely the work of other investigators whose efforts have focused heretofore in the 2nd trimester," said Lenetix president and CEO Leonard H. ....

Gene Abnormality Found to Predict Childhood Leukemia Relapse

... disease. And, indeed, it did." The researchers' analysis indicated that identifying IKAROS alterations may be clinically useful and will complement existing diagnostic tests and measurement of minimal residual disease levels. While a clinical test for alterations of IKAROS could prove ...

Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial

... The data indicate that the HeartMate II achieved statistical superiority to the control group patients by an overwhelming margin. These findings complement the experience with the device in bridge-to-transplantation (BTT) patients, both in our pivotal trial and as a commercially available device since ...

VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease

... at 8:30am ET on Monday, November 10. The webcast will be archived for 30 days following the presentation. About VIA-2291 VIA-2291 is designed to complement current standard of care therapies that treat cardiac risk factors, such as statins, antiplatelet and blood pressure medications. VIA-2291 is ...

Raptor Pharmaceuticals Provides Update on Targeting Platforms

... bind better and demonstrate enhanced biological potency compared to proteins or peptides derived from the naturally occurring RAP sequence and will complement our growing in-house set of targeting peptides." Raptor also announced that the Patent Office of Japan will issue Raptor's patent application ...

ORBIS and Alcon Call Attention to the Aging Eye

... ORBIS Flying Eye Hospital and through ORBIS-sponsored hospital-based programs in China, Ethiopia, India, Peru and other countries. These engineers complement the hundreds of volunteer doctors and nurses who make ORBIS' medical training possible. Since 1979, Alcon has provided more than $8 million in ...

Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)

... metabolism. Based on the strength of these results and the unique Empatic mechanism of action, the Company selected this product combination to complement our Contrave clinical development program. Forward-Looking Statements Orexigen cautions you that statements included in this press release that ...
Other Contents
(Date:8/20/2014)... a study of 158 pregnant teenagers in Rochester, NY, ... intentional consumption of ice, cornstarch, vacuum dust, baby powder ... Cornell study. , Moreover, such teens had significantly lower ... eat nonfood substances. , Pregnant teens, regardless of pica, ... lead to iron deficiency and anemia. Low iron in ...
(Date:8/20/2014)... the University of Tbingen, Arizona State University, the Wellcome ... Health Institute (Swiss TPH) isolated Mycobacterium pinnipedii ... 1000 years old. The pathogen is a relative of ... causes disease in humans today. These researchers assume that ... coast. "The link to sea lions was unexpected" comments ...
(Date:8/20/2014)... the Oklahoma Medical Research Foundation a five-year, $14.5 million ... bacteria,s effects on humans. , For 10 years, ... studied the human immune response to anthrax bacteria as ... original funding came soon after anthrax-laced letters killed five ... attacks of Sept. 11, 2001. , The long-term ...
Breaking Biology News(10 mins):Pica in pregnant teens linked to low iron 2$14.5 million grant awarded to continue anthrax studies 2
(Date:8/22/2014)... with severe disabilities and multiple chronic conditions are screened ... disabilities or no chronic conditions, a new study has ... women with moderate disabilities or women with only one ... scientist with the Li Ka Shing Knowledge Institute of ... disabilities often have other measures of social vulnerability, such ...
(Date:8/22/2014)... NY (PRWEB) August 22, 2014 Ticket ... Caputo tickets in Kalamazoo, New Orleans, Albuquerque and Rapid ... death, the “Long Island Medium,” Theresa Caputo, allows just that. ... Island. She is part of a close knit family who ... speaking with a spiritual healer, realized she had a chance ...
(Date:8/22/2014)... “Dr. Luciana Show – Aging and Falling” is currently ... finding it challenging to stay on top of post-production tasks ... of students, so the editing of the episodes will take ... she recently entered it into the festival circuit. , ... actor/screenwriter Gregory Graham , the aging and falling show ...
(Date:8/22/2014)... (ESMO), the leading pan-European organisation representing medical oncology ... individuals receiving the Society,s esteemed annual awards. The ... Joensuu and Peter Boyle on the occasion of ... , Carsten Bokemeyer will receive the ESMO Award ... cancer discovery into real benefit at patient level. ...
(Date:8/22/2014)... approx. 265,000 Danes are acutely admitted to medical departments ... University and Aarhus University Hospital now shows that many ... are sent home again without receiving a diagnosis ... hospitalisation., "Naturally, there is no need for a diagnosis ... is a serious illness. So some patients will always ...
Breaking Medicine News(10 mins):Health News:Women with severe, chronic health issues are screened for breast cancer less often 2Health News:Theresa Caputo Tickets in Kalamazoo at Wings Stadium, Saenger Theatre in New Orleans, Kiva Auditorium in Albuquerque and Rapid City at Don Barnett Arena Now Available 2Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 2Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 3Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 4Health News:ESMO honors outstanding oncology professionals 2Health News:ESMO honors outstanding oncology professionals 3Health News:Many patients are discharged without a diagnosis 2
Other TagsOther Tags